IntroductionPsoriasis is a chronic inflammatory, immune‐mediated skin disease affecting 1–3% of the industrialized population. There are several treatment options available for moderate to severe psoriasis that can provide improvements in clinical assessments of skin symptoms [e.g. Psoriasis Area and Severity Index (PASI), Physician's Global Assessment (PGA) and Dermatology Life Quality Index (DLQI)]. The disease is associated with both physical and psychological impairments, and hence, optimal control requires adherence to continuous treatment.PROSPECT (Observational, Descriptive Study of Prior and Concomitant Psoriasis Treatments in Subjects Receiving Secukinumab in the Routine Treatment of Moderate to Severe Plaque‐type Psoriasis; EUPAS10715) is a descriptive study designed to assess prior and concomitant use of psoriasis treatments in subjects receiving secukinumab, and the duration of transition periods from prior treatments to secukinumab treatment in Germany. Previous studies report the prevalence of psoriasis for individuals of all ages in Germany as 2.00% (95% confidence internal (CI): 1.98–2.20) and 2.53% (95% CI: 2.50–2.56). German and European treatment guidelines for psoriasis recommend combinations of various psoriasis treatments for selected subjects and purposes. For example, topical treatments are often combined with both conventional systemic treatments and biologics, and conventional systemic treatments are sometimes combined with biologics. A recent international consensus report
Journal of the European Academy of Dermatology & Venereology – Wiley
Published: Jan 1, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud